Avalo Therapeutics, Inc. (AVTX) free cash flow
Avalo Therapeutics, Inc. (AVTX) generated free cash flow of -$51.46M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$49.06M. Figures as of 18 Nov 2026, 11:53 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Free cash flow, fiscal 2025
- -$51.46M
- Highest on record
- $12.56Mfiscal 2017
- Lowest on record
- -$71.01Mfiscal 2021
- Fiscal years on record
- 132013–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Avalo Therapeutics, Inc. free cash flow, in more detail
Across the 13 fiscal years on record (2013–2025), the highest was $12.56M in fiscal 2017 and the lowest -$71.01M in fiscal 2021.
Free cash flow by fiscal year
Avalo Therapeutics, Inc. free cash flow, year by year
| Fiscal year | Free cash flow | Change | Year ended |
|---|---|---|---|
| 2025 | -$51.46M | — | |
| 2024 | -$49.06M | — | |
| 2023 | -$30.68M | — | |
| 2022 | -$26.85M | — | |
| 2021 | -$71.01M | — | |
| 2020 | -$40.60M | — | |
| 2019 | -$19.40M | — | |
| 2018 | -$3.69M | 129.4% down | |
| 2017 | $12.56M | — | |
| 2016 | -$14.61M | — | |
| 2015 | -$10.18M | — | |
| 2014 | -$15.54M | — | |
| 2013 | -$11.51M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.
How to read it
It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.
Avalo Therapeutics, Inc., figure by figure
- Avalo Therapeutics, Inc. market cap
- Avalo Therapeutics, Inc. revenue
- Avalo Therapeutics, Inc. earnings
- Avalo Therapeutics, Inc. earnings per share (EPS)
- Avalo Therapeutics, Inc. P/E ratio
- Avalo Therapeutics, Inc. P/S ratio
- Avalo Therapeutics, Inc. P/B ratio
- Avalo Therapeutics, Inc. operating margin
- Avalo Therapeutics, Inc. dividend
- Avalo Therapeutics, Inc. shares outstanding
- Avalo Therapeutics, Inc. total debt
- Avalo Therapeutics, Inc. cash on hand
- Avalo Therapeutics, Inc. total assets
- Avalo Therapeutics, Inc. return on equity (ROE)
- Avalo Therapeutics, Inc. return on invested capital (ROIC)
Avalo Therapeutics, Inc. (AVTX) overview: price, valuation and scorecard
Avalo Therapeutics, Inc. free cash flow: questions and answers
What is Avalo Therapeutics, Inc.'s free cash flow?
Avalo Therapeutics, Inc. (AVTX) generated free cash flow of -$51.46M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$49.06M.
What are the highest and lowest free cash flow figures on record for Avalo Therapeutics, Inc.?
Across the 13 fiscal years on record (2013–2025), the highest was $12.56M in fiscal 2017 and the lowest -$71.01M in fiscal 2021.
How is Avalo Therapeutics, Inc.'s free cash flow calculated?
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Avalo Therapeutics, Inc. it is on record here for 13 fiscal years, 2013 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: free cash flow
All stocks guides →- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
- How a DCF valuation works, and why inputs swing it
A discounted cash flow (DCF) valuation estimates what a business is worth today by forecasting the cash it will produce and discounting each year's cash back at a required rate of return. Because most of the value lies far in the future, a one-point change in growth or discount rate can move the answer by a quarter.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Avalo Therapeutics, Inc. (AVTX) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/AVTX/free-cash-flow
Underlying data: the company's filings with the SEC and Yahoo Finance.